Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05465954 · ClinicalTrials.gov registry record · Phase 2
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
A Phase 2 study of Recurrent Gliosarcoma and Recurrent Glioblastoma, IDH-Wildtype, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT05465954 is a Phase 2 study of Recurrent Gliosarcoma and Recurrent Glioblastoma, IDH-Wildtype that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 54 participants, above the 29-participant average among 7 other Recurrent Gliosarcoma trials with a reported enrollment target (86% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05465954, a Phase 2 study of Recurrent Gliosarcoma and Recurrent Glioblastoma, IDH-Wildtype, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
- BIOLOGICAL Efineptakin alfa
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2028-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05465954
The ClinicalTrials.gov registry entry for NCT05465954 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 29-participant average among 7 other Recurrent Gliosarcoma trials with a reported enrollment target (86% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Gliosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05465954 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05465954 about?
NCT05465954 is a clinical study titled "Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma". This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibo...
What is the current status of trial NCT05465954?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2023-01-24. Estimated completion is 2028-10-15.
What conditions does trial NCT05465954 study?
This clinical trial studies the following conditions: Recurrent Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, High Grade Astrocytic Tumor.
What interventions are being tested in trial NCT05465954?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE), Efineptakin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT05465954?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05465954 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Gliosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
-
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RECRUITING · Phase 1
-
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
ACTIVE NOT RECRUITING · Phase 1
-
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.